• Curocell filed for South Korean regulatory clearance on Oct. 27, 2026, to amend its Phase 1/2 CRC01 leukemia trial.
• The amendment would separate the adult acute lymphoblastic leukemia protocol following marketing authorization for relapsed or refractory diffuse large B-cell lymphoma.
• The separation aims to support independent, more efficient operation of the leukemia study.
• The trial evaluates CRC01’s tolerability, safety and efficacy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curocell Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261027900604), on October 27, 2026, and is solely responsible for the information contained therein.